BCAX Stock: Price, Earnings History and SEC Filings
Bicara Therapeutics Inc. (BCAX) last traded at $9.13, down 6.17% on the latest session and down 50.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.82 against an analyst estimate of $-0.77, a miss of 6.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BCAX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.82 | $-0.77 | -6.49% |
| Mar 2026 | May 11, 2026 | $-0.93 | $-0.64 | -45.31% |
| Dec 2025 | Mar 30, 2026 | $-0.68 | $-0.72 | +5.56% |
| Sep 2025 | Nov 10, 2025 | $-0.67 | $-0.55 | -21.82% |
BCAX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How BCAX reacts to earnings
Across its last 8 earnings releases, BCAX moved 5.0% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-11 | Before open | -14.32% |
| 2026-05-11 | Before open | +1.51% |
| 2026-03-30 | Before open | +3.65% |
| 2026-02-26 | After close | -0.12% |
| 2025-11-10 | Before open | -4.85% |
| 2025-08-12 | Before open | +4.80% |
| 2025-05-13 | Before open | -8.10% |
| 2025-03-27 | Before open | +2.29% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BCAX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$138M | -$107M | – | $-2.52 |
| 2024 | – | -$68M | -$75M | – | $-4.05 |
| 2023 | – | -$52M | -$46M | – | $-89.61 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BCAX
- 8-K · Aug 25, 2026Material agreement, Financial statements and exhibits
- 10-Q · Aug 11, 2026
- 8-K · Aug 11, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 28, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 10, 2026Shareholder vote
- 8-K · May 21, 2026Other events, Financial statements and exhibits
- 10-Q · May 11, 2026
- 8-K · May 11, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 27, 2026
- 10-K · Mar 30, 2026
Insider filing activity
BCAX insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BCAX news
- Bicara Therapeutics Inc BCAXOct 30, 2026 · morningstar.com
- Analysts Offer Insights on NA Companies: Bicara Therapeutics Inc. (BCAX) and Microsoft (MSFT)Oct 27, 2026 · theglobeandmail.com
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc. (BCAX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.